{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:49:05Z","timestamp":1778942945434,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006447","name":"UZH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009691","name":"Nuovo-Soldati Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Swiss Cancer League","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.leukres.2021.106608","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:20:52Z","timestamp":1620044452000},"page":"106608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-3326","authenticated-orcid":false,"given":"Marco M","family":"B\u00fchler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scheinost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-1384","authenticated-orcid":false,"given":"Tharshika","family":"Thavayogarajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Haralambieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewerton","family":"Marques Maggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-2385","authenticated-orcid":false,"given":"S\u00edlvia","family":"Be\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier A.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106608_bib0005","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","author":"Ferrero","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106608_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2021.106608_bib0015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","article-title":"SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination","volume":"20","author":"Daddacha","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2021.106608_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","article-title":"SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage","volume":"123","author":"Clifford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106608_bib0025","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/1078-0432.CCR-15-3103","article-title":"A quantitative analysis of subclonal and clonal gene mutations before and after therapy in chronic lymphocytic leukemia","volume":"22","author":"Amin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2021.106608_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-017-0036-5","article-title":"SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia","volume":"8","author":"Johansson","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2021.106608_bib0035","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106608_bib0040","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106608_bib0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2021.106608_bib0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ijc.33202","article-title":"The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: an analysis of the MCL Younger and Elderly trial","volume":"148","author":"Roider","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2021.106608_bib0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2021.106608_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2021.106608_bib0065","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2021.106608_bib0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1189\/jlb.4HI0714-338RR","article-title":"SAMHD1\u2019s protein expression profile in humans","volume":"98","author":"Schmidt","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.leukres.2021.106608_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107640","article-title":"SAMHD1 limits the efficacy of Forodesine in leukemia by protecting cells against the cytotoxicity of dGTP","volume":"31","author":"Davenne","year":"2020","journal-title":"Cell Rep."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:15Z","timestamp":1758934875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":15,"alternative-id":["S0145212621001090"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106608","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.09.140376","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106608"}}